Reata Pharmaceuticals Inc

Reata Pharmaceuticals — FY2021 Earnings Presentation

25 slides from Reata Pharmaceuticals's earnings presentation, Feb 28, 2022

  1. Slide 1: 4th Quarter and Full Year 2021 Financial Results and Update on Clinical Development Programs

    4th Quarter and Full Year 2021 Financial Results and Update on Clinical Development Programs February 28, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Development Update |

  4. Slide 4: Regulatory Update on Omaveloxolone for Patients with Friedreich's Ataxia

    Regulatory Update on Omaveloxolone for Patients with Friedreich’s Ataxia NDA: New Drug Application Obtained Fast Track Designation

  5. Slide 5: Update on Bardoxolone Program

    Update on Bardoxolone Program CRL: Complete Response Letter; FDA: United States Food and Drug Administration We will continue to work with the FDA to confirm our next steps on our Alport syndrome program FALCON protocol amendment submitted to FDA Type A meeting requested

  6. Slide 6: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  7. Slide 7: Friedreich's Ataxia: No Approved Therapy

    Friedreich’s Ataxia: No Approved Therapy 1Rummey C, et.al. Neurol Genet. 2019; 2Rummey C, et.al. E Clinical Medicine. 2020; 3Tsou AY, et. al. J Neurol Sci. 2011; 42020 IQVIA claims data and projected diagnosed; 5Estimated by Reata and the Friedreich’s Ataxia Research Alliance (FARA) based on publicl

  8. Slide 8: MOXIe Part 2: Summary of Efficacy

    MOXIe Part 2: Summary of Efficacy One of the largest completed global interventional studies in patients with FA Enrolled a wide and representative range of patients with FA Baseline mFARS: 20 to 80 Age: 16 to 40 years old MOXIe Part 2 met its mFARS primary endpoint Improvement observed in all subse

  9. Slide 9: MOXIe Extension: Delayed-Start Analysis Study Design

    MOXIe Extension: Delayed-Start Analysis Study Design FDA suggested an exploratory, post-hoc analysis, the Delayed Start Analysis Established analysis methodology used in other neurological indications1 MOXIe Extension is ongoing to continue evaluating efficacy and safety of omaveloxolone in patients

  10. Slide 10: Delayed-Start Analysis: Results Consistent with Persistent Effect on Disease Course

    Ext. 72 (Δ2) Delayed-Start Analysis: Results Consistent with Persistent Effect on Disease Course Non-inferiority test criteria met More than 50% of the difference between groups in mFARS observed at MOXIe Part 2 Week 48 (-2.25, p=0.037) was preserved at MOXIe Extension Week 72 (-3.51, p=0.016) Point

  11. Slide 11: Delayed-Start Analysis: Parallel Annualized Slopes

    Delayed-Start Analysis: Parallel Annualized Slopes Consistent with Persistent Effect on Disease Course Longitudinal analysis was used to calculate annualized slopes in MOXIe Extension Incorporates all available data from the MOXIe Extension as of August 2021 data cut-off Placebo-to-Omav (0.45 ± 0.38

  12. Slide 12: MOXIe Part 2: Summary of Adverse Events

    MOXIe Part 2: Summary of Adverse Events AEs generally mild to moderate in severity ALT and AST increases may be related to the pharmacological activity of omaveloxolone Not associated with other indicators of liver injury SAEs SAEs reported in five omaveloxolone-treated patients (10%) and three plac

  13. Slide 13: Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases

    MOXIe results provide proof of concept for use of omaveloxolone in other neurological diseases Mitochondrial dysfunction and neuroinflammation are common features of FA and other neurological diseases Omaveloxolone and analogs may be applicable to the diseases listed below, and we have observed prom

  14. Slide 14: Chronic Kidney Disease Program Updates

    Chronic Kidney Disease Program Updates

  15. Slide 15: AYAME Phase 3 Diabetic CKD Outcomes Trial in Japan

    AYAME Phase 3 Diabetic CKD Outcomes Trial in Japan Kyowa Kirin, our strategic collaborator in Japan is sponsoring AYAME Randomized, double-blind, placebo-controlled, registrational trial of bardoxolone in patients with diabetic CKD in Japan Primary endpoint: time to onset of ≥ 30% decline in eGFR or

  16. Slide 16: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD

    International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Protocol amendment filed with the FDA: Endpoints Primary: off-treatment eGFR change from baseline at Week 108 No treatment discontinuation at Year 1 Exploratory : additional

  17. Slide 17: RTA 901 HSP90 Modulator for Diabetic Neuropathy

    RTA 901 HSP90 Modulator for Diabetic Neuropathy

  18. Slide 18: RTA 901: Study in Patients with Diabetic Peripheral Neuropathic Pain

    RTA 901: Phase 2 Study in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) RTA 901 is a novel, small-molecule, orally bioavailable C-terminal Hsp90 inhibitor and Hsp70 inducer1 DPNP is a serious complication of diabetes mellitus2-4 Associated with substantial morbidity, including often debi

  19. Slide 19: Financial & Operational Update

    Financial & Operational Update

  20. Slide 20: Significant U.S. Commercial Opportunity and Launch Readiness

    Significant U.S. Commercial Opportunity and Launch Readiness 1Estimated by Reata and the Friedreich’s Ataxia Research Alliance (FARA) based on publicly available data and from Vankan P, J Neurochem 2013; 22019 IQVIA claims data and projected diagnosed; 3Eight Collaborative Clinical Research Networks

  21. Slide 21: Key Items at Dec 31, 2021 and Financial Summary

    Key Items at Dec 31, 2021 Cash and Cash Equivalent $590M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding Updated Cash Guidance: Based on our operational plans, we are extending cash guidance from mid-2024 to the end of 2024 Financial Summary 1Excludes

  22. Slide 22: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  23. Slide 23: Concluding Remarks

    Concluding Remarks

  24. Slide 24: Reata at a Glance

    Reata at a Glance Initiated rolling submission of NDA for omaveloxolone in FA Plan to complete submission by the end of Q1 2022 Plan to initiate Phase 2 study of RTA 901 in DPNP in second half of 2022 Received CRL and will work with FDA to confirm next steps on Alport program FALCON protocol amendme

  25. Slide 25: Thank you

    Thank you

Reata Pharmaceuticals — FY2021 Earnings Presentation on 6ix